TRAW: Rasio rega marang prakiraan pendapatan trawspharma.com

Logo grafis Traws Pharma Inc (TRAW)

The forward price-to-sales ratio demonstrates the cost of capital dynamics, where 3.20 represents the latest metric reading. High barriers to entry are created by expensive R&D and FDA oversight. Meanwhile, Traws Pharma, Inc. (TRAW) relies on its debt-free balance sheet and molecule protection, while the development of small-molecule influenza treatments ensures a prolonged commercialization period for its products.

Traws Therapeutics - Multiplikator Forward P/S TRAW (periode 04.04.2024 - 17.08.2026)

Rincian analitis perusahaan Traws Pharma, Inc.

- rega saham lan target rega konsensus:
Kutipan saham Traws Pharma|TRAW - Rega prakiraan analis
- informasi kapitalisasi pasar:
Nilai pasar TRAW|TRAW - Nilai Dipunlarasaken Utang lan Kas
- indikator nilai buku ekuitas:
Nilai Buku saben Saham Traws Pharma|TRAW - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih trawspharma.com|TRAW - Gunggung Aset Perusahaan
- informasi babagan utang lan solvabilitas:
Utang marang Ekuitas Traws Pharma, Inc.|TRAW - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Traws Pharma|TRAW - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku TRAW|TRAW - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Traws Pharma|Rasio cepet trawspharma.com
- rincian asil keuangan lan kelipatan valuasi:
TRAW - Bathi resik|Bathi sing dikarepake Traws Pharma, Inc.|TRAW - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Traws Pharma|TRAW - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA TRAW|TRAW - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Traws Pharma|TRAW - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan trawspharma.com|TRAW - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Traws Pharma, Inc.
- data total pendapatan lan volume dodolan:
TRAW - Volume dodolan perusahaan|Prakiraan volume dodolan Traws Pharma|TRAW - Kapitalisasi marang pendapatan|Multiplikator forward rega marang pendapatan TRAW
Ringkesan analisis perusahaan:TRAW (Traws Therapeutics)
Produk asli Traws Pharma Inc

The investor is assessing growth potential by comparing the current market value of Traws Pharma, Inc. (TRAW) with projected revenue based on 10-K and 10-Q filings. This ratio measures the premium for future sales, which, for a developer of unique antiviral drugs with low demand elasticity, reflects market confidence in the business's pricing power, as clearly demonstrated by the expected P/S dynamics.

Pesaing langsung

Gilead Sciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CDTX (Cidara Therapeutics Corp)|NVAX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CVAC (CureVac Pharma)|VALN: Multiplikator Forward P/S|vir.bio (VIR) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan SIGA|Multiplikator forward rega marang pendapatan Emergent BioSolutions Inc (EBS)|Rasio rega marang prakiraan pendapatan Atea Pharmaceuticals Inc (AVIR)|Rasio kapitalisasi marang dodolan sing dikarepake invivyd.com|Enanta Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan INO|HLVX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan KLRS|DYAI: Multiplikator Forward P/S|NanoViricides - Rega forward marang dodolan|TLPH (Talphera, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S cocrystalpharma.com|Rasio rega marang prakiraan pendapatan Dogwood Therapeutics, Inc. (DWTX)|QLGN (Qualigen Therapeutics Inc) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AlloVir ALVR|VBIV - Multiplikator forward rega marang pendapatan|Virios - Multiplikator Forward P/S|VXRT - Multiplikator Forward P/S